Showing 1861-1870 of 2105 results for "".
- Hispanic/Latino Patients Experience MS Onset Earlier than White Participants, New Research Suggestshttps://practicalneurology.com/news/hispaniclatino-patients-experience-ms-onset-earlier-than-white-participants-new-research-suggests/2470201/According to research presented at the 2023 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), the age at onset (AAO) of multiple sclerosis (MS) was on average 5 years earlier for Hispanic/Latino patient
- Study Assesses the Quality of Life and Unmet Needs of Geriatric and Advanced MS Patientshttps://practicalneurology.com/news/study-assesses-the-quality-of-life-and-unmet-needs-of-geriatric-and-advanced-ms-patients/2470195/A study performed by members of the Medical College of Wisconsin analyzed quality of life (QOL) and rates of depression of patients with advanced multiple sclerosis (A-MS) and geriatric MS (G-MS) compared with younger patie
- FDA Grants Fast Track Designation to Factor XIa Inhibitor Milvexian to Treat Stroke, ACS, and AFhttps://practicalneurology.com/news/fda-grants-fast-track-designation-to-factor-xia-inhibitor-milvexian-to-treat-stroke-acs-and-af/2470191/The investigational factor XIa (FXIa) inhibitor milvexian (Janssen Pharmaceuticals, Johnson & Johnson, Beerse, Belgium; Bristol Myers Squibb, New York, NY) was granted Fast Track designation by the Food and Drug Adminis
- Wearable Sleep Monitor Receives Third FDA Clearancehttps://practicalneurology.com/news/wearable-sleep-monitor-receives-third-fda-clearance/2470144/Wesper (New York, NY) announced th
- New Nasal Spray Treatment for Migraine Approvedhttps://practicalneurology.com/news/new-nasal-spray-treatment-for-migraine-approved/2470137/The Food and Drug Administration (FDA) approved a new nasal spray for the treatment of acute migraine with or without aura in adults. Zavegepant (Zavzpret; Pfizer, New York, NY) represents the first intranasal-administered
- Next Generation DHODH Inhibitor Helps Delay Disability in Those with Relapsing-Remitting MShttps://practicalneurology.com/news/next-generation-dhodh-inhibitor-helps-delay-disability-in-those-with-relapsing-remitting-ms/2470124/New clinical trial data suggest that vidofludimus calcium therapy (VidoCa; Immunic, New York, NY) for r
- Antidepressants Safe in Those Taking Ozanimod for Relapsing MShttps://practicalneurology.com/news/antidepressants-safe-in-those-taking-ozanimod-for-relapsing-ms/2470123/Data presented at the Americas Committee for Treatment & Research in Multiple Sclerosis (ACTRIMS) Forum 2023 suggest that concurrent administration of ozanimod (Zeposia; Bristol Myers Squibb, New York, NY) with selectiv
- Ozanimod Comparable to Diroximel Fumarate for Relapsing-Remitting MShttps://practicalneurology.com/news/ozanimod-comparable-to-diroximel-fumarate-for-relapsing-remitting-ms/2470121/According to results from a matching-adjusted indirect comparison study, ozanimod (Zeposia; Bristol Myers Squibb, New York, NY) had
- Reboxetine Helpful in Obstructive Sleep Apnea Treatmenthttps://practicalneurology.com/news/reboxetine-helpful-in-obstructive-sleep-apnea-treatment/2470118/According to results presented in the Journal of Clinical Sleep Medicine, treatment of obstructive sleep apnea (OSA) with reboxetine (Edronax; Pfizer, New York, NY) was effective at reducing OSA symptom severity. Res
- FDA Approves Monoclonal Antibody for Treating Relapsing MShttps://practicalneurology.com/news/fda-approves-monoclonal-antibody-for-treating-relapsing-ms/2470088/The Food and Drug Administration (FDA) approved ublituximab (Briumvi; TG Therapeutics, New York, NY) for treating relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.